Russia isn't world's first to develop Covid-19 vaccine: Kiran Mazumdar-Shaw

"If launching a vaccine prior to completion of Phase 3 trials is acceptable to Russia, well so be it," Mazumdar-Shaw said

Kiran Mazumdar-Shaw
"It doesn't make them the world's first vaccine as several other vaccine programmes are even more advanced," she said
Press Trust of India Bengaluru
1 min read Last Updated : Aug 13 2020 | 6:17 PM IST

Biotechnology industry veteran Kiran Mazumdar-Shaw has questioned Russian claims of developing the world's first safe coronavirus vaccine, citing absence of data on clinical trials and "more advanced" programmes elsewhere.

The world has not seen any data on Phase 1 or 2 clinical trials conducted by Moscow-based Gamaleya Research Institute, the Executive Chairperson of Bengaluru-headquartered Biocon Ltd said.

"If launching a vaccine prior to completion of Phase 3 trials is acceptable to Russia, well so be it," Mazumdar-Shaw told PTI.

ALSO READ: How rolling out Russia's Covid-19 vaccine without proper test can backfire

"But it doesn't make them the world's first vaccine as several other vaccine programmes are even more advanced," she added.

Russia announced on Tuesday it had become the first country to grant regulatory approval to a Covid-19 vaccine.

The first dose of the vaccine-Sputnik-V, developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministry, was administered to Russian President Vladimir Putin's daughter.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineKiran Mazumdar-ShawRussia

Next Story